Free Trial

PROCEPT BioRobotics (PRCT) Stock Forecast & Price Target

PROCEPT BioRobotics logo
$34.83 +0.08 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$35.40 +0.58 (+1.65%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PROCEPT BioRobotics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
2
Buy
7

Based on 10 Wall Street analysts who have issued ratings for PROCEPT BioRobotics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a sell rating, 2 have given a hold rating, and 7 have given a buy rating for PRCT.

Consensus Price Target

$70.00
100.98% Upside
According to the 10 analysts' twelve-month price targets for PROCEPT BioRobotics, the average price target is $70.00. The highest price target for PRCT is $95.00, while the lowest price target for PRCT is $55.00. The average price target represents a forecasted upside of 100.98% from the current price of $34.83.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PRCT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for PROCEPT BioRobotics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRCT Analyst Ratings Over Time

TypeCurrent Forecast
10/9/24 to 10/9/25
1 Month Ago
9/9/24 to 9/9/25
3 Months Ago
7/11/24 to 7/11/25
1 Year Ago
10/10/23 to 10/9/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$70.00$73.22$87.50$78.17
Forecasted Upside100.98% Upside85.28% Upside54.46% Upside5.43% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

PRCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

PROCEPT BioRobotics Stock vs. The Competition

TypePROCEPT BioRoboticsMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside100.98% Upside1,077.15% Upside172.96% Upside
News Sentiment Rating
Neutral News

See Recent PRCT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (E+)
9/16/2025BTIG Research
2 of 5 stars
Ryan Zimmerman
Ryan Zimmerman
5 of 5 stars
Reiterated RatingNeutral
9/2/2025Oppenheimer
2 of 5 stars
Suraj Kalia
Not Rated
UpgradeMarket PerformOutperform$60.00+49.37%
8/7/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$75.00 ➝ $58.00+44.28%
8/7/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$80.00 ➝ $55.00+40.99%
7/15/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$71.00 ➝ $68.00+20.89%
7/9/2025Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$70.00+18.61%
4/25/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$104.00 ➝ $84.00+59.82%
4/11/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$90.00 ➝ $70.00+40.55%
11/14/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$95.00+2.98%
9/16/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$75.00 ➝ $99.00+19.26%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
10/16/2023Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$37.00+24.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:03 PM ET.


PRCT Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for PROCEPT BioRobotics is $70.00, with a high forecast of $95.00 and a low forecast of $55.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PRCT shares.

According to analysts, PROCEPT BioRobotics's stock has a predicted upside of 100.98% based on their 12-month stock forecasts.

Over the previous 90 days, PROCEPT BioRobotics's stock had 1 upgrade by analysts.

PROCEPT BioRobotics has been rated by research analysts at BTIG Research, Morgan Stanley, Oppenheimer, Piper Sandler, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like PROCEPT BioRobotics more than other "medical" companies. The consensus rating for PROCEPT BioRobotics is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how PRCT compares to other companies.


This page (NASDAQ:PRCT) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners